Glucocorticoid receptor blockade as disease-modifying treatment for depression with childhood trauma: a study protocol of the RESET-medication study

被引：0
|
作者：
Linsen, F. [1 ]
Verhoeven, J. [1 ]
Bet, P. [1 ]
Penninx, B. [1 ]
Meijer, O. [2 ]
Vinkers, C. [1 ]
机构：
[1] Amsterdam UMC Locat VUmc, Dept Psychiat, Amsterdam, Netherlands
[2] Leiden UMC, Dept Med, Div Endocrinol, Leiden, Netherlands
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2021年 / 53卷
关键词：
D O I：
10.1016/j.euroneuro.2021.10.772
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.0700
引用
收藏
页码：S513 / S513
页数：1
相关论文
共 50 条
  • [31] The CLARITY Study: Efficacy Outcomes Among Patients Who Received Disease-modifying Drugs Prior To Treatment With Cladribine Tablets
    Vermersch, P.
    Rammohan, K.
    Damian, D.
    Jack, D.
    Harty, G.
    Wong, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 49 - 49
  • [32] IMPACT STUDY: IMCY-0098 PROOF OF ACTION IN TYPE 1 DIABETES, ON THE WAY TO A SPECIFIC DISEASE-MODIFYING TREATMENT
    Van Rampelbergh, J.
    Dunger, D.
    Dayan, C.
    Ali, M. Alhadj
    Mander, A.
    Tree, T.
    Bovy, N.
    Zeyen, C.
    Mathieu, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A163 - A164
  • [33] Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study
    Giedraitiene, N.
    Taluntiene, V
    Kaubrys, G.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [34] Exploring the effect of Disease-Modifying Treatment on Paramagnetic Rim Lesions: a real-world cross-sectional study
    Barbuti, Elena
    Piervincenzi, Claudia
    Gianni, Costanza
    Gangemi, Emma
    Nistri, Riccardo
    Altieri, Marta
    Conte, Antonella
    Pantano, Patrizia
    Pozzilli, Carlo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 906 - 906
  • [35] The CLARITY study: efficacy outcomes among patients who received disease-modifying therapies prior to treatment with cladribine tablets
    Vermersch, P.
    Rammohan, K.
    Damian, D.
    Jack, D.
    Harty, G.
    Wong, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 301 - 302
  • [36] How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years
    Epelbaum, Stephane
    Paquet, Claire
    Hugon, Jacques
    Dumurgier, Julien
    Wallon, David
    Hannequin, Didier
    Jonveaux, Therese
    Besozzi, Annick
    Pouponneau, Stephane
    Hommet, Caroline
    Blanc, Frederic
    Berly, Laetitia
    Julian, Adrien
    Paccalin, Marc
    Pasquier, Florence
    Bellet, Julie
    Boutoleau-Bretonniere, Claire
    Charriau, Thiphaine
    Rouaud, Olivier
    Madec, Olivier
    Mouton, Aurelie
    David, Renaud
    Bekadar, Samir
    Fabre, Roxane
    Liegey, Emmanuelle
    Deberdt, Walter
    Robert, Philippe
    Dubois, Bruno
    BMJ OPEN, 2019, 9 (06):
  • [37] Effect of type of disease-modifying antirheumatic drugs on depression and anxiety of patients with rheumatoid arthritis in Saudi Arabia: a cross-sectional study
    Baghdadi, Leena R.
    Alhassan, Mohammed K.
    Alotaibi, Fawaz H.
    Alsuwaida, Anas A.
    Shehadah, Ali E.
    Alzahrani, Mohammed T.
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [38] Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol
    Vivash, Lucy
    Johns, Hannah
    Churilov, Leonid
    MacPhail, Sara
    Casillas-Espinosa, Pablo
    Malpas, Charles
    Shultz, Sandy R.
    Tailby, Chris
    Wijayath, Manori
    Reutens, David
    Gillinder, Lisa
    Perucca, Piero
    Carney, Patrick
    Nicolo, John-Paul
    Lawn, Nicholas
    Kwan, Patrick
    Velakoulis, Dennis
    Hovens, Christopher M.
    O'Brien, Terence J.
    BMJ OPEN, 2023, 13 (10):
  • [39] Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study
    Kondo, Akihiro
    Ikeguchi, Ryotaro
    Kitagawa, Kazuo
    Shimizu, Yuko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [40] Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
    van der Leeuw, Matthijs S.
    Welsing, Paco M. J.
    de Hair, Maria J. H.
    Jacobs, Johannes W. G.
    Marijnissen, Anne C. A.
    Linn-Rasker, Suzanne P.
    Fodili, Faouzia
    Bos, Reinhard
    Tekstra, Janneke
    van Laar, Jacob M.
    TRIALS, 2020, 21 (01)
12345